Skip to main content

Table 1 Characteristics of NPC patients and healthy controls

From: Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma

Characteristics

Discovery set (n = 47)

Validation set (n = 16)

NPC patients (n = 22)

healthy controls (n = 25)

p value

NPC patients (n = 8)

healthy controls (n = 8)

p value

Median age

(y, range)

48 (25–68)

45 (25–65)

0.933

50 (20–69)

46 (26–61)

0.311

Gender

  

0.756

  

0.619

 Male

14 (63.6%)

16 (64.0%)

 

6 (75%)

5 (62.5%)

 

 Female

8 (36.4%)

9 (36.0%)

 

2 (25%)

3 (37.5%)

 

Smoking

  

0.713

  

0.642

 Yes

10 (45.5%)

10 (40.0%)

 

4 (50%)

5 (62.5%)

 

 No

12 (54.5%)

15 (60.0%)

 

4 (50%)

3 (37.5%)

 

Drinking

  

0.825

  

0.334

 Yes

3 (13.6%)

4 (16.0%)

 

1 (12.5%)

0

 

 No

19 (86.4%)

21 (84.0%)

 

7 (87.5%)

8 (100%)

 

Karnofsky performance score

  

0.129

  

0.334

 ≤ 80

2 (9.1%)

0

 

1 (12.5%)

0

 

 ≥ 90

20 (90.9%)

25 (100/%)

 

7 (87.5%)

8 (100%)

 

Pathology (WHO classification)

 Non-keratinizing (typeII-III)

22 (100.0%)

  

8 (100.0%)

  

Pre-EBV DNA (copies/mL)

Median (rang)

1,597,817 (0–59,200,000)

0

0.001

1,959,159 (0–2,860,000)

0

0.022

LDH (U/L)

Median (range)

168 (102–684)

115 (101–298)

0.368

171 (116–339)

137 (102–274)

0.119

HGB(g/L)

Median (range)

127 (81–169)

135 (121–168)

0.289

130 (93–172)

129 (117–148)

0.085

ALB(g/L)

Median (range)

41.3 (30–55)

46 (37–56)

0.041

41 (34–56)

44 (38–55)

0.215

CRP (mg/L)

Median (range)

2 (0–119.1)

1.2 (0–32)

0.025

8.1 (0–45.4)

2.3 (0–29)

0.063

T category a

 T1

6 (27.3%)

  

1 (12.5%)

  

 T2

4 (18.2%)

  

1 (12.5%)

  

 T3

5 (22.7%)

  

3 (37.5%)

  

 T4

7 (31.8%)

  

3 (37.5%)

  

N category a

 N0

1 (4.5%)

  

0

  

 N1

6 (27.3%)

  

3 (37.5%)

  

 N2

12 (54.6%)

  

4 (50.0%)

  

 N3

3 (13.6%)

  

1 (12.5%)

  

Overall stage a

 I

1 (4.5%)

  

0

  

 II

5 (22.7%)

  

2 (25.0%)

  

 III

6 (27.3%)

  

5 (50.0%)

  

 IVA-B

10 (45.5%)

  

1 (12.5%)

  
  1. Abbreviations: WHO world health organization, Pre-EBV DNA pre-treatment plasma Epstein-Barr Virus DNA, LDH lactate dehydrogenase, HGB hemoglobin, ALB albumin, CRP C-reaction protein
  2. aAccording to the 8th AJCC/UICC staging system